Mr. Rene Goehrum reports

BIOSYENT RELEASES FINANCIAL RESULTS FOR Q1 2024

BioSyent Inc. released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include:

• Return on equity for TTM (trailing 12 months) March 31, 2024, was 21 per cent, as compared with 15 per cent for TTM March 31, 2023;
• During Q1 2024, repurchased for cancellation a total of 156,200 common shares under a normal course issuer bid (NCIB);
• Paid quarterly cash dividends of 4.5 cents per common share on March 15, 2024, an increase of 12.5 per cent from the previous quarterly dividend.

"Our Canadian pharmaceutical business got off to a fast start in Q1 2024, with 18-per-cent revenue growth over the comparative period," said Rene Goehrum, president and chief executive officer of BioSyent. "All of our Canadian pharmaceutical brands contributed to this growth during the quarter. Our three launch brands, FeraMAX Pd Maintenance 45, Inofolic and Gelclair, also contributed modest incremental growth during Q1 2024. We remain focused on continuing to grow our Canadian pharmaceutical business during the remainder of the year, with continued selling and promotional investment in our launch brands. I look forward to reporting on our progress in 2024."

The CEO's presentation on the Q1 2024 results is available on the company's website.

The company's interim unaudited condensed consolidated financial statements and management's discussion and analysis for the three months ended March 31, 2024, and March 31, 2023, will be posted on SEDAR+ on May 16, 2024.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been successfully developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals who treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this news release, the company has 11,585,169 common shares outstanding.

We seek Safe Harbor.